This review helps pharmacists position finerenone across the CKD spectrum, distinguish it from steroidal mineralocorticoid receptor antagonists, and manage its hyperkalemia and eGFR-dip profile.
Finerenone now has randomized evidence for cardiorenal protection across type 2 diabetic and non-diabetic albuminuric chronic kidney disease (CKD), and should be considered as an add-on to maximally tolerated renin-angiotensin system (RAS) blockade with a structured potassium monitoring plan rather than reserved for advanced disease.
Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), is established for cardiorenal protection in type 2 diabetes (T2D) with albuminuric CKD on the basis of the FIDELIO-DKD and FIGARO-DKD trials, and is endorsed by Kidney Disease: Improving Global Outcomes (KDIGO) and American Diabetes Association (ADA) guidance. Its mechanism, pharmacokinetics, and outcome data increasingly separate it from steroidal MRAs such as spironolactone. New trial data are now pushing its documented role into non-diabetic CKD.
FIND-CKD extended finerenone's benefit to non-diabetic albuminuric CKD, slowing total eGFR decline by 0.7 ml/min/1.73 m2/yr and reducing a composite of kidney or cardiovascular events (hazard ratio [HR] 0.77), an indication not previously addressed by guidelines. In parallel, BARACK-D showed low-dose spironolactone (25 mg/day) added no cardiovascular benefit in moderate non-albuminuric CKD (HR 1.05) with roughly two-thirds discontinuing within 6 months, sharpening the contrast between agents. A 2024 KDIGO cardiorenal consensus reframed post-initiation eGFR dips as generally benign.
The KDIGO 2024 CKD guideline and KDIGO 2022 Diabetes in CKD guideline, along with ADA Standards of Care, currently position finerenone as an add-on to RAS inhibition (and SGLT2 inhibition) specifically in T2D with albuminuric CKD. FIND-CKD creates evidence ahead of guidelines for the non-diabetic albuminuric population, a gap that future updates are likely to close. The KDIGO 2024 cardiorenal consensus also highlights divergent eGFR thresholds between CKD and heart failure (HF) guidance and underuse of urine albumin-to-creatinine ratio (UACR) testing.
| Source | Key finding | Grade / Verdict |
|---|---|---|
|
Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD
Study · American journal of cardiovascular drugs : drugs, devices, and other interventions
comparative context / agent differentiation Contrasts BARACK-D's negative spironolactone result and high discontinuation with finerenone's pooled FINE-HEART benefits to differentiate nonsteroidal from steroidal MRAs.
|
Spironolactone showed no cardioprotection in moderate CKD (HR 1.05; 95% CI 0.81-1.37) | Grade: Moderate Confirmatory |
|
KDIGO Consensus Reframes Kidney Function Changes in Heart Failure
Study · Kidney international
cardiorenal consensus / monitoring framework KDIGO cardiorenal consensus reframes post-initiation eGFR dips as generally benign and flags underuse of UACR and divergent CKD versus HF thresholds.
|
Narrative guideline, no single statistic (eGFR decline up to 30% considered benign) | Grade: Low Confirmatory |
|
Finerenone Slows eGFR Decline in Non-Diabetic CKD
Study · Unknown
new pillar evidence (non-diabetic CKD) FIND-CKD extends finerenone's documented cardiorenal role into non-diabetic albuminuric CKD, ahead of current guidelines.
|
Slowed total eGFR decline by 0.7 ml/min/1.73 m2/yr (95% CI 0.3-1.1; P<0.001); event composite HR 0.77 (0.60-0.99) | Grade: Moderate Practice-changing |
|
Finerenone Slows CKD Progression in Type 2 Diabetes
Study · New England Journal of Medicine
pivotal renal-primary evidence FIDELIO-DKD is the pivotal trial establishing finerenone's kidney and cardiovascular benefit in T2D with albuminuric CKD.
|
Kidney composite reduced 18% (HR 0.82; 95% CI 0.73-0.93; NNT 29) | Grade: High Practice-changing |
|
Finerenone Cuts Heart Failure Events in Preserved Ejection Fraction
Study · New England Journal of Medicine
pivotal cardiovascular evidence (earlier CKD) FIGARO-DKD extends finerenone's cardiovascular benefit to earlier-stage albuminuric CKD, complementing the renal-primary FIDELIO-DKD.
|
CV composite absolute reduction 1.8 points (NNT 47), driven by HF hospitalization (HR 0.71; 95% CI 0.56-0.90) | Grade: High Practice-changing |
Subscribe to PharmD Signal for the complete practice recommendations on every topic, plus every deep analysis we publish.
Become a Subscriber →